Exercise capacity · COPD
1 finding from 1 review
Functional performance · COPD
1 finding from 1 review
Symptoms of dyspnoea · COPD
1 finding from 1 review
Health‐related quality of life · COPD
1 finding from 1 review
Minor adverse events assessed: related to intervention only (e.g. redness) · COPD
1 finding from 1 review
Peripheral muscle endurance/fatigability · COPD
1 finding from 1 review
Thigh muscle size · COPD
1 finding from 1 review
Exercise capacity · COPD
1 finding from 1 review
Functional performance · COPD
The review found no eligible studies for this question.
1 finding from 1 review
no estimate extracted
Studies not reported
No studies found
Symptoms of dyspnoea · COPD
1 finding from 1 review
Health‐related quality of life · COPD
1 finding from 1 review
Minor adverse events assessed: related to intervention only (e.g. redness) · COPD
NMES showed no clear difference in minor adverse events assessed: related to intervention only (e.g.… compared with usual care (with or without sham NMES) (low certainty).
1 finding from 1 review
Peripheral muscle force · COPD
1 finding from 1 review
FVC (% predicted) Change from baseline · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
Adverse events ‐ pneumonia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: pneumonia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Adverse effects: anaemia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: anaemia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Thrombocytopenia · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in adverse events: thrombocytopenia 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Health‐related quality of life (HAQ‐DI) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review
All‐cause mortality 12‐month · people with connective tissue disease‐associated interstitial lung disease
Cyclophosphamide showed no clear difference in all‐cause mortality 12‐month compared with mycophenolate (low certainty).
1 finding from 1 review
Change in lung function (diffusing capacity of the lung for carbon monoxide (DLCO) % predicted) · people with connective tissue disease‐associated interstitial lung disease
1 finding from 1 review